Millipore Sigma Vibrant Logo
 

analyzer


241 Results Advanced Search  
Showing
Products (25)
Documents (53)
Site Content (163)

Narrow Your Results Use the filters below to refine your search

Document Type

  • (48)
  • (2)
  • (1)
  • (1)
  • (1)
Can't Find What You're Looking For?
Contact Customer Service

 

  • Identification of eusynstyelamide B as a potent cell cycle inhibitor following the generation and screening of an ascidian-derived extract library using a real time cell ... 25329705

    Ascidians are marine invertebrates that have been a source of numerous cytotoxic compounds. Of the first six marine-derived drugs that made anticancer clinical trials, three originated from ascidian specimens. In order to identify new anti-neoplastic compounds, an ascidian extract library (143 samples) was generated and screened in MDA-MB-231 breast cancer cells using a real-time cell analyzer (RTCA). This resulted in 143 time-dependent cell response profiles (TCRP), which are read-outs of changes to the growth rate, morphology, and adhesive characteristics of the cell culture. Twenty-one extracts affected the TCRP of MDA-MB-231 cells and were further investigated regarding toxicity and specificity, as well as their effects on cell morphology and cell cycle. The results of these studies were used to prioritize extracts for bioassay-guided fractionation, which led to the isolation of the previously identified marine natural product, eusynstyelamide B (1). This bis-indole alkaloid was shown to display an IC50 of 5 µM in MDA-MB-231 cells. Moreover, 1 caused a strong cell cycle arrest in G2/M and induced apoptosis after 72 h treatment, making this molecule an attractive candidate for further mechanism of action studies.
    Document Type:
    Reference
    Product Catalog Number:
    04-1116

  • Glycome mapping on DNA sequencing equipment. 17406262

    Here we provide a detailed protocol for the analysis of protein-linked glycans on DNA sequencing equipment. This protocol satisfies the glyco-analytical needs of many projects and can form the basis of 'glycomics' studies, in which robustness, high throughput, high sensitivity and reliable quantification are of paramount importance. The protocol routinely resolves isobaric glycan stereoisomers, which is much more difficult by mass spectrometry (MS). Earlier methods made use of polyacrylamide gel-based sequencers, but we have now adapted the technique to multicapillary DNA sequencers, which represent the state of the art today. In addition, we have integrated an option for HPLC-based fractionation of highly anionic 8-amino-1,3,6-pyrenetrisulfonic acid (APTS)-labeled glycans before rapid capillary electrophoretic profiling. This option facilitates either two-dimensional profiling of complex glycan mixtures and exoglycosidase sequencing, or MS analysis of particular compounds of interest rather than of the total pool of glycans in a sample.
    Document Type:
    Reference
    Product Catalog Number:
    3130

  • Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. 22077787

    Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common forms of inheritable Parkinson's disease and likely play a role in sporadic disease as well. LRRK2 is a large multidomain protein containing two key groups, a Ras-like GTP binding domain and a serine, threonine kinase domain. Mutations in the LRRK2 gene that associate with Parkinson's disease reside primarily within the two functional domains of the protein, suggesting that LRRK2 function is critical to the pathogenesis of the disease. The most common LRRK2 mutation increases kinase activity, making LRRK2 kinase inhibition an attractive target for small molecule drug development. However, the physiological function of LRRK2 kinase as well as its endogenous protein substrates remains poorly understood and has hindered drug development efforts. Recent advances in LRRK2 biology have revealed several potential cellular roles, interacting proteins, and putative physiological substrates. Together, a picture emerges of a complex multifunctional protein that exists in multiple cellular compartments. Through unclear mechanisms, LRRK2 kinase regulates cytoskeleton architecture through control of protein translation, phosphorylation of cytoskeletal proteins, and response to cellular stressors. This article will briefly cover some interesting recent studies in LRRK2 cellular biology and highlight emerging cellular models of LRRK2 kinase function.
    Document Type:
    Reference
    Product Catalog Number:
    MAB3418
    Product Catalog Name:
    Anti-MAP2 Antibody, clone AP20

  • Tbr1 regulates regional and laminar identity of postmitotic neurons in developing neocortex. 20615956

    Areas and layers of the cerebral cortex are specified by genetic programs that are initiated in progenitor cells and then, implemented in postmitotic neurons. Here, we report that Tbr1, a transcription factor expressed in postmitotic projection neurons, exerts positive and negative control over both regional (areal) and laminar identity. Tbr1 null mice exhibited profound defects of frontal cortex and layer 6 differentiation, as indicated by down-regulation of gene-expression markers such as Bcl6 and Cdh9. Conversely, genes that implement caudal cortex and layer 5 identity, such as Bhlhb5 and Fezf2, were up-regulated in Tbr1 mutants. Tbr1 implements frontal identity in part by direct promoter binding and activation of Auts2, a frontal cortex gene implicated in autism. Tbr1 regulates laminar identity in part by downstream activation or maintenance of Sox5, an important transcription factor controlling neuronal migration and corticofugal axon projections. Similar to Sox5 mutants, Tbr1 mutants exhibit ectopic axon projections to the hypothalamus and cerebral peduncle. Together, our findings show that Tbr1 coordinately regulates regional and laminar identity of postmitotic cortical neurons.
    Document Type:
    Reference
    Product Catalog Number:
    2100
    Product Catalog Name:
    Protein-Concentrate Kit (Micro)

  • Metabolic changes and net portal flux in dairy cows fed a ration containing rumen-protected fat as compared to a control diet. 18096942

    Feeding rumen-protected fat (RPF) is an alternative to increase energy density of the diet and therefore energy intake in dairy cows. To investigate metabolic and endocrine changes in dairy cows fed either a diet containing RPF (FD) or a control diet with an increased amount of cornstarch (SD), 3 Holstein cows (83 +/- 1 d in milk) were fitted with catheters in the portal vein, a mesenteric artery, and 2 mesenteric veins. Cows were fed consecutively SD and FD for 3 wk, respectively. In FD, cornstarch [92 g/kg of dry matter (DM)] was replaced by 50 g of RPF/kg of DM (mainly C16:0 and C18:1). Tracer infusions of NaH(13)CO3 and D-[U-(13)C6]glucose were performed into a jugular vein to measure rate of appearance and oxidation of glucose. Arterial and portal blood samples were collected to measure concentrations of glucose, lactate, volatile fatty acids, nonesterified fatty acids, beta-hydroxybutyrate, triglycerides, AA, insulin, and glucagon. Concomitantly, para-aminohippurate was infused into a mesenteric vein for measurement of portal plasma flow. Although DM intake was slightly lower in FD, protein and energy intakes were unaffected by diets. Milk and lactose yields were higher in FD than SD. Arterial plasma glucose concentration was lower with FD than SD, whereas nonesterified fatty acid and triglyceride concentrations were higher in FD. Glucagon concentration and glucagon-to-insulin ratio were both augmented by FD feeding. When feeding FD, greater milk and lactose yields, but not energy-corrected milk, were associated with elevated lipid status and higher glucagon concentrations but occurred despite lower plasma glucose concentration and were not linked with changes in whole body glucose rate of appearance. This study suggests a glucose-sparing effect allowing an enhanced lactose synthesis when feeding RPF.
    Document Type:
    Reference
    Product Catalog Number:
    PI-12K
    Product Catalog Name:
    Porcine Insulin RIA